Eisai Company, Limited

Koukichi Harada

Isao Yamatsu

Shinya Abe

Hiroyuki Yoshimura

Kazuo Okano

Mitsuaki Miyamoto

Tetsuya Kawahara

Shuhei Miyazawa

Takeshi Suzuki

Naoyuki Shimomura

Shigeru Souda

Yoshimasa Machida

Osamu Asano

Kouichi Katayama

Kenzo Muramoto

Kouji Nakamoto

Tohru Fujimori

Richard S Clark

Hironori Ikuta

Kenji Hayashi

Youji Yamagishi

Kozo Akasaka

Kouji Yamada

Hiroshi Obaishi

Satoshi Katayama

Hajime Tsunoda

Yoshimori Sakuma

Tsutomu Kawata

Junsaku Nagaoka

Tsutomu Yoshimura

Hiromasa Suzuki

Takashi Inoue

Kenichi Chiba

Ryoichi Hashida

Toru Horie

Takashi Mori

Kenichi Kusube

Akiharu Kajiwara

Shinichi Kitamura

Hiroshi Shirota

Shigeki Hibi

Katsuya Tagami

Yasushi Okamoto

Takashi Yamanaka

Masanobu Shinoda

Koichi Abe

Naoki Kobayashi

Kaname Miyamoto

Hirotoshi Numata

Toshihiko Yamauchi

Hirsohi Shirota

Richar S Clark

Naoyuki Kimomura

Akiko Nakahama

The present invention provides a therapeutic agent for fundamentally preventing, treating or ameliorating dermatosis, such as, non-infectious dermatosis, which include psoriasis and atopic dermatitis. The therapeutic agent comprises a glycerol derivative represented by the formula (I): ##STR1## wherein A is a group represented by the formula: ##STR2## or single bond; R.sup.1 is a group represented by the formula: ##STR3## wherein R.sup.2 is a methoxyphenyl group or methyl group, X is an atom or atomic group which may become an anion or a group represented by the formula: ##STR4## or a pharmacologically acceptable salt thereof as an active ingredient.

Therapeutic agent for dermatosis

A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are useful in the pharmaceutical field, especially in treating allergic diseases. ##STR1## in which R.sup.1 and R.sup.2 are hydrogen or an alkyl, R.sup.3 is hydrogen or a halogen, R.sup.4 is hydrogen or an alkyl, X is --OCO--, and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

1,4-diazepine derivative and its pharmaceutical use

A glycerin derivative having the following formula (I) or (I') and a pharmacologically acceptable salt thereof are useful to treat diseases caused by the platelet activating factor. ##STR1##

Glycerin derivative and its pharmacological use

A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. ##STR1## in which R.sup.1 and R.sup.2 are hydrogen or an alkyl, R.sup.3 is hydrogen or a halogen, R.sup.4 is hydrogen or an alkyl, X is --OCO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. ##STR1## in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is --OOO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to treat allergic diseases: ##STR1## in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is --OCO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

A triazolo-1,4-azepine compound of the below given formulas and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. ##STR1## in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is --OCO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals

The present invention is a quinone derivative which exhibits excellent therapeutic activity represented by the general formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein A stands for a group represented by the formula: ##STR2## (wherein R.sup.3, R.sup.4 and R.sup.5 is the same or different from each other and each stand for a hydrogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxy group, an alkoxyalkyl group, an alkoxyalkoxy group, a cycloalkylalkoxy group, a thiol group or a thioalkyl group, with the proviso that R.sup.3 and R.sup.4 are each a lower alkoxy group

Quinone derivatives

Compounds of the formula: ##STR1## where R.sup.1 is a hydrogen atom or a lower alkyl group;

Naphthalene derivatives

A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases, ##STR1## in which R.sup.1 and R.sup.2 are hydrogen or an alkyl, R.sup.3 is hydrogen or a halogen, R.sup.4 is hydrogen or an alkyl, X is --OCO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

The present invention relates to a naphthalene derivative. More particularly, it relates to a naphthalene derivative exhibiting an excellent activity as a drug.

A triazolo-1,4-di-azepine compound of the below given formulas and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. ##STR1## in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is --OCO--, --NHCO--, --CO-- or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

Growing community of inventors

Ibaraki, Japan

Koukichi Harada